Clinical Trial

Criteria for Selecting First-line Metastatic Treatment for Patients With Urothelial Carcinoma

Study acronym: FLORAL
Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated January 14, 2026 (before its estimated April 2026 completion). Its status may not reflect the trial's current state.
Summary
The standard first-line treatment for metastatic urothelial carcinoma has become the combination of Enfortumab Vedotin and Pembrolizumab following the publication of the EV-302 study results at the end of 2024. Another standard remains in 2025 for patients who are not eligible for the EV Pembrolizumab combination, namely platinum-based chemotherapy +/- avelumab in cases of non-progression. The objective of the FLORAL study is to determine the characteristics of these patients and the reasons that led clinicians to prefer a first-line treatment based on platinum salts.
Trial Details
NCT Number NCT07339878
Lead Sponsor University Hospital, Strasbourg, France
Conditions Metastatic Urothelial Carcinoma
Enrollment 50 participants
Start Date 2025-04-20
Primary Completion 2026-04 (estimated)
Study Completion 2026-04-20 (estimated)
Updated on ClinicalTrials.gov 2026-01-14